Rongzhen Xu

Rongzhen Xu

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2015 in Protein & Cell
Verified
Journal Article
Open access
PDF file
HZHong Zhou
Hong Zhou
RXRongzhen Xu
Rongzhen Xu
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by a chromosome translocation that generates the Bcr-Abl oncogene encoding a constitutive kinase activity. Despite remarkable success in controlling CML at chronic phase by Bcr-Abl tyrosine kinase inhibitors (TKIs), a significant proportion of CML patients treated with TKIs develop drug resistance due to the inability of TKIs to kill leukemia stem cells (LSCs) that are responsible for initiation, drug resistance, and relapse of CML. Therefore, there is an urgent need for more potent and safer therapies against leukemia stem cells for curing CML. A number of LSC-associated targets and corresponding signaling pathways, including CaMKII-γ, a critical molecular switch for co-activating multiple LSC-associated signaling pathways, have been identified over the past decades and various small inhibitors targeting LSC are also under development. Increasing evidence shows that leukemia stem cells are the root of CML and targeting LSC may offer a curable treatment option for CML patients. This review summarizes the molecular biology of LSC and its-associated targets, and the potential clinical application in chronic myeloid leukemia.

1 October 2013 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
ZMZhipeng Meng
Zhipeng Meng
TLTao Li
Tao Li
XMXiaoxiao Ma
Xiaoxiao Ma
XWXiaoqiong Wang
Xiaoqiong Wang
CNCarl Van Ness
Carl Van Ness
WHWendong Huang
Wendong Huang
Liver cancer is the third leading cause of cancer deaths worldwide but no effective treatment toward liver cancer is available so far. Therefore, there is an unmet medical need to identify novel therapies to efficiently treat liver cancer and improve the prognosis of this disease. Here, we report that berbamine and one of its derivatives, bbd24, potently suppressed liver cancer cell proliferation and induced cancer cell death by targeting Ca2+/calmodulin-dependent protein kinase II (CAMKII). Furthermore, berbamine inhibited the in vivo tumorigenicity of liver cancer cells in NOD/SCID mice and downregulated the self-renewal abilities of liver cancer–initiating cells. Chemical inhibition or short hairpin RNA–mediated knockdown of CAMKII recapitulated the effects of berbamine, whereas overexpression of CAMKII promoted cancer cell proliferation and increased the resistance of liver cancer cells to berbamine treatments. Western blot analyses of human liver cancer specimens showed that CAMKII was hyperphosphorylated in liver tumors compared with the paired peritumor tissues, which supports a role of CAMKII in promoting human liver cancer progression and the potential clinical use of berbamine for liver cancer therapies. Our data suggest that berbamine and its derivatives are promising agents to suppress liver cancer growth by targeting CAMKII. Mol Cancer Ther; 12(10); 2067–77. ©2013 AACR.

1 July 2017 in Cancer Cell
Verified
Journal Article
Closed access
YGYing Gu
Ying Gu
JZJiawei Zhang
Jiawei Zhang
XMXiaoxiao Ma
Xiaoxiao Ma
BKByung-Wook Kim
Byung-Wook Kim
HWHailong Wang
Hailong Wang
WHWendong Huang
Wendong Huang

17 July 2007 in Cellular Microbiology
Verified
Journal Article
Open access
PDF file
WZWei Zhang
Wei Zhang
XZXuzhao Zhang
Xuzhao Zhang
CTC. Tian
C. Tian
TWTao Wang
Tao Wang
PSPhuong Thi Nguyen Sarkis
Phuong Thi Nguyen Sarkis
RXRongzhen Xu
Rongzhen Xu
The cytidine deaminase apolipoprotein B mRNA editing catalytic subunit‐3 (APOBEC3) proteins have been identified as potent inhibitors of diverse retroviruses, retrotransposons and hepatitis B virus (HBV). The mechanism of APOBEC3 proteins in the control of HBV infection, however, is less clear. Here we report that APOBEC3B (A3B) displays dual inhibitory effects on both HBsAg and HBeAg expression as well as HBV core‐associated DNA synthesis. Heterogeneous nuclear ribonucleoprotein K (hnRNP K), a positive regulator of HBV expression, has been identified as a major interaction partner of A3B protein. A3B protein inhibited the binding of hnRNP K to the enhancer II of HBV (Enh II), and S gene transcription of HBV. Moreover, A3B directly suppressed HBV S gene promoter activity. Individual variation in A3B expression was observed in both normal primary hepatocytes and liver tissues. Interestingly, A3B was able to inhibit CMV and SV40 promoter‐mediated gene expression. In conclusion, A3B suppresses HBV replication in hepatocytes by inhibiting hnRNP K‐mediated transcription and expression of HBV genes as well as HBV core DNA synthesis. In addition, A3B protein may be a broad antiviral host factor. Thus, regulated A3B expression may contribute to non‐cytolytic HBV clearance in vivo.

1 January 2006 in Leukemia Research
Verified
Journal Article
Closed access
RXRongzhen Xu
Rongzhen Xu
QDQinghua Dong
Qinghua Dong
YYYingzi Yu
Yingzi Yu
XZXiaoying Zhao
Xiaoying Zhao
XGXiaoxian Gan
Xiaoxian Gan
XYXiao-Fang Yu
Xiao-Fang Yu

20 January 2022 in Advanced Science
Verified
Journal Article
Open access
PDF file
YXYing Xu
Ying Xu
QYQingfeng Yu
Qingfeng Yu
PWPing Wang
Ping Wang
ZWZhaoxing Wu
Zhaoxing Wu
LZLei Zhang
Lei Zhang
RXRongzhen Xu
Rongzhen Xu
MYC oncogene is involved in the majority of human cancers and is often associated with poor outcomes, rendering it an extraordinarily desirable target, but therapeutic targeting of c‐Myc protein has been a challenge for >30 years. Here, WBC100, a novel oral active molecule glue that selectively degrades c‐Myc protein over other proteins and potently kills c‐Myc overexpressing cancer cells is reported. WBC100 targets the nuclear localization signal 1 (NLS1)–Basic–nuclear localization signal 2 (NLS2) region of c‐Myc and induces c‐Myc protein degradation through ubiquitin E3 ligase CHIP mediated 26S proteasome pathway, leading to apoptosis of cancer cells. In vivo, WBC100 potently regresses multiple lethal c‐Myc overexpressing tumors such as acute myeloid leukemia, pancreatic, and gastric cancers with good tolerability in multiple xenograft mouse models. Identification of the NLS1–Basic–NLS2 region as a druggable pocket for targeting the “undruggable” c‐Myc protein and that single‐agent WBC100 potently regresses c‐Myc overexpressing tumors through selective c‐Myc proteolysis opens new perspectives for pharmacologically intervening c‐Myc in human cancers.